DK190486A - Xanthiner - Google Patents

Xanthiner Download PDF

Info

Publication number
DK190486A
DK190486A DK190486A DK190486A DK190486A DK 190486 A DK190486 A DK 190486A DK 190486 A DK190486 A DK 190486A DK 190486 A DK190486 A DK 190486A DK 190486 A DK190486 A DK 190486A
Authority
DK
Denmark
Prior art keywords
xanthines
ester
phosphonyl
tetrazolyl
adenosine
Prior art date
Application number
DK190486A
Other languages
English (en)
Other versions
DK190486D0 (da
DK169271B1 (da
Inventor
Susan Mary Daluge
Harry Jefferson Leighton
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of DK190486D0 publication Critical patent/DK190486D0/da
Publication of DK190486A publication Critical patent/DK190486A/da
Application granted granted Critical
Publication of DK169271B1 publication Critical patent/DK169271B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/20—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

og Z er carboxy, sulfonyl eller i>hosphonyl eller en al-kylester, aralkylester eller arylester heraf, eller er 5-tetrazolyl, og X5 og Xe er ens eller forskellige og betegner oxygen eller svovl, eller salte eller solvater heraf, fremstilles ved forskellige fremgangsmader. Forbindelserne finder anvendelse til human og veterinær terapi, navnlig til lidelser forbundet med adenosins celleoverfladevirkninger.
DK190486A 1985-04-27 1986-04-24 8-Phenylxanthinderivater, fremgansmåde til fremstilling heraf, farmaceutisk præparat indeholdende en sådan forbindelse, samt en sådan forbindelse til anvendelse til terapi DK169271B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8510758 1985-04-27
GB858510758A GB8510758D0 (en) 1985-04-27 1985-04-27 Compounds

Publications (3)

Publication Number Publication Date
DK190486D0 DK190486D0 (da) 1986-04-24
DK190486A true DK190486A (da) 1986-10-28
DK169271B1 DK169271B1 (da) 1994-09-26

Family

ID=10578311

Family Applications (1)

Application Number Title Priority Date Filing Date
DK190486A DK169271B1 (da) 1985-04-27 1986-04-24 8-Phenylxanthinderivater, fremgansmåde til fremstilling heraf, farmaceutisk præparat indeholdende en sådan forbindelse, samt en sådan forbindelse til anvendelse til terapi

Country Status (22)

Country Link
US (2) US4879296A (da)
EP (1) EP0203721B1 (da)
JP (1) JPH0788381B2 (da)
KR (1) KR860008176A (da)
AP (1) AP22A (da)
AT (1) ATE77088T1 (da)
AU (1) AU581507B2 (da)
CA (1) CA1286666C (da)
DE (1) DE3685608T2 (da)
DK (1) DK169271B1 (da)
ES (1) ES8800945A1 (da)
FI (1) FI861750L (da)
GB (1) GB8510758D0 (da)
GR (1) GR861107B (da)
HU (1) HUT41027A (da)
IE (1) IE60022B1 (da)
IL (1) IL78605A (da)
MC (1) MC1743A1 (da)
NO (1) NO861643L (da)
NZ (1) NZ215948A (da)
PT (1) PT82451B (da)
ZA (1) ZA863132B (da)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4710503A (en) * 1985-02-07 1987-12-01 Euroceltique S.A. 6-thioxanthine derivatives
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
GB8610136D0 (en) * 1986-04-25 1986-05-29 Wellcome Found Compounds
AT388500B (de) * 1987-10-27 1989-06-26 Wellcome Found Antivirale 8-phenylxanthine
US5298508A (en) * 1988-07-19 1994-03-29 The United States Of America As Represented By The Department Of Health And Human Services Irreversible inhibitors of adenosine receptors
US5310916A (en) * 1988-07-19 1994-05-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Trifunctional agents useful as irreversible inhibitors of A1-adenosine receptors
AU5436790A (en) * 1989-04-19 1990-11-16 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Sulfer-containing xanthine derivatives as adenosin antagonists
WO1991016056A1 (en) * 1990-04-16 1991-10-31 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Use of purinergic receptor agonists as antineoplastic agents
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
ATE180482T1 (de) * 1991-11-08 1999-06-15 Kyowa Hakko Kogyo Kk Xanthinderivate zur behandlung der demenz
US5336769A (en) * 1992-02-17 1994-08-09 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
US5300298A (en) * 1992-05-06 1994-04-05 The Pennsylvania Research Corporation Methods of treating obesity with purine related compounds
TW252044B (da) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
JP2613355B2 (ja) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
CA2112031A1 (en) * 1992-12-24 1994-06-25 Fumio Suzuki Xanthine derivatives
US5521315A (en) * 1993-01-12 1996-05-28 Cell Therapeutics, Inc. Olefin substituted long chain compounds
AU6781194A (en) * 1993-05-03 1994-11-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
WO1995011681A1 (en) * 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
GB9415529D0 (en) * 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
US6025361A (en) 1994-12-13 2000-02-15 Euro-Celtique, S.A. Trisubstituted thioxanthines
EP0799040B1 (en) * 1994-12-13 2003-08-20 Euroceltique S.A. Trisubstituted thioxanthines
DE69531506T2 (de) 1994-12-13 2004-06-24 Euroceltique S.A. Arylthioxanthine
US5733932A (en) * 1995-01-06 1998-03-31 The Picower Institute For Medical Research Compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions
US6268373B1 (en) 1995-06-07 2001-07-31 Euro-Celtique S.A. Trisubstituted thioxanthines
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
AU2603197A (en) 1996-04-10 1997-10-29 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Use of an a1 adenosine receptor agonist to treat cerebral ischaemia
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
US5864037A (en) 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
US6294541B1 (en) 1996-06-06 2001-09-25 Euro-Celtique S.A. Purine derivatives having phosphodiesterase IV inhibition activity
US5728560A (en) * 1996-06-14 1998-03-17 Enzon, Inc. Method of treating CD4+ T cell lymphopenia in immuno-compromised patients
US5744473A (en) * 1996-09-16 1998-04-28 Euro-Celtique, S.A. PDE IV inhibitors: "bis-compounds"
GB9703044D0 (en) 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6063363A (en) * 1997-05-27 2000-05-16 Goodwin; Gary J Treatment for upper respiratory tract infections with potassium salts
CN1294590A (zh) 1997-12-12 2001-05-09 欧罗赛铁克股份有限公司 通过2－硫代黄嘌呤制备3－取代腺嘌呤的方法
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6303619B1 (en) * 1998-03-12 2001-10-16 University Of Virginia Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors
GB9817623D0 (en) * 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
US6319928B1 (en) 1998-11-30 2001-11-20 Euro-Celtique, S.A. Purine derivatives having phosphodiesterase IV inhibition activity
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
CA2367143A1 (en) 1999-04-02 2000-10-12 Euro-Celtique S.A. Purine derivatives having phosphodiesterase iv inhibition activity
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US7253176B1 (en) * 2000-05-04 2007-08-07 K.U. Leuven Research & Development Immunosuppressive effects of 8-substituted xanthine derivatives
US6670334B2 (en) 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
NZ556354A (en) * 2001-10-01 2008-10-31 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
ATE520694T1 (de) 2001-11-09 2011-09-15 Gilead Palo Alto Inc A2b-adenosinrezeptorantagonisten
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20040072848A1 (en) * 2002-02-26 2004-04-15 Huber Brian E Methods of treating irritable bowel syndrome and functional dyspepsia
EP1513848A4 (en) * 2002-06-12 2005-11-09 Biogen Idec Inc METHOD FOR TREATING ISCHEMIA REPERFUSION INJURIES WITH ADENOSINE RECEPTOR ANTAGONISTS
EP1601649A4 (en) * 2003-02-19 2009-03-04 Endacea Inc A1-adenosine receptor antagonistic
RU2318825C2 (ru) * 2003-05-06 2008-03-10 Си Ви Терапьютикс, Инк. Производные ксантина в качестве антагонистов a2b аденозинового рецептора
CA2524778C (en) * 2003-05-06 2013-01-29 Cv Therapeutics, Inc. Xanthine derivatives as a2b adenosine receptor antagonists
US7247639B2 (en) * 2003-06-06 2007-07-24 Endacea, Inc. A1 adenosine receptor antagonists
AU2005267706B2 (en) * 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
WO2006023272A1 (en) * 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
US7576069B2 (en) * 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
US20060058322A1 (en) * 2004-09-01 2006-03-16 Dewan Zeng Method of wound healing using A2B adenosine receptor antagonists
WO2007092936A2 (en) * 2006-02-08 2007-08-16 University Of Virginia Patent Foundation Method to treat gastric lesions
US8178509B2 (en) 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
US8193200B2 (en) 2007-01-04 2012-06-05 University Of Virginia Patent Foundation Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2602795A (en) * 1950-06-24 1952-07-08 Searle & Co Hydroxyalkyl alkyl derivatives of 5-nitroso-6-amino-1, 2, 3, 4-tetrahydro-2, 4-pyrimidinedione
US4452788A (en) * 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4612315A (en) * 1984-10-26 1986-09-16 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active 1,3-dipropyl-8-phenylxanthine derivatives
US4696932A (en) * 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
DE3522230A1 (de) * 1985-06-21 1987-01-02 Thomae Gmbh Dr K Neue 2-arylimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
US4981857A (en) 1991-01-01
ZA863132B (en) 1987-12-30
EP0203721A3 (en) 1988-06-08
IL78605A0 (en) 1986-08-31
DK190486D0 (da) 1986-04-24
MC1743A1 (fr) 1987-02-26
AP8600036A0 (en) 1986-02-01
FI861750A7 (fi) 1986-10-28
PT82451B (pt) 1988-11-30
AP22A (en) 1988-07-20
EP0203721B1 (en) 1992-06-10
IL78605A (en) 1989-07-31
JPH0788381B2 (ja) 1995-09-27
NO861643L (no) 1986-10-28
AU5670786A (en) 1986-10-30
GR861107B (en) 1986-08-04
JPS6242986A (ja) 1987-02-24
FI861750L (fi) 1986-10-28
AU581507B2 (en) 1989-02-23
HUT41027A (en) 1987-03-30
DK169271B1 (da) 1994-09-26
DE3685608D1 (de) 1992-07-16
FI861750A0 (fi) 1986-04-25
DE3685608T2 (de) 1992-12-24
ES8800945A1 (es) 1987-12-01
GB8510758D0 (en) 1985-06-05
IE60022B1 (en) 1994-05-18
US4879296A (en) 1989-11-07
NZ215948A (en) 1989-10-27
CA1286666C (en) 1991-07-23
ES554380A0 (es) 1987-12-01
EP0203721A2 (en) 1986-12-03
IE861104L (en) 1986-10-27
KR860008176A (ko) 1986-11-12
ATE77088T1 (de) 1992-06-15
PT82451A (en) 1986-05-01

Similar Documents

Publication Publication Date Title
DK190486A (da) Xanthiner
DE3650772D1 (de) Derivate von Indazole-3-carboxamide und -3-carboxylsäure
NO784324L (no) Fremgangsmaate for fremstilling av polymerisater av akrylsyre og/eller metakrylsyre
DK536381A (da) 8-arylalkyl-3-phenyl-3-nortropanoler eller syreadditionssalte deraf fremgangsmaade til deres fremstilling samt deres anvendelse
IT1129671B (it) Cella elettrolitica per la dissociazione dell'acqua
MX161889A (es) Procedimiento para tenir el acido desoxiribonucleico de celulas vivientes de mamiferos
IT1162608B (it) Cella elettrolitica cloro-alcali e relativo procedimento di elettrolisi
BR8606974A (pt) Tratamento eletroquimico das ligninas
DK70083A (da) Fremgangsmaade til fremstilling af pyrroleddikesyreamider eller salte deraf
IT1115163B (it) Procedimento di piroidrolisi per rivestimento di celle per la riproduzione di alluminio consumati
BR8601180A (pt) Processo para controlar a adicao de a1f3 a um eletrolito
DK135380A (da) Fremgangsmaade til fremstilling af imidazobenzodiazepiner eller syreadditionssalte deraf samt ved fremgangsmaaden anvendelige mellemprodukter og udgangsmaterialer
DK39581A (da) Fremgangsmaade til fremstilling af benzodiazepinderivater eller farmaceutisk acceptable syreadditionssalte deraf samt ved fremgangsmaaden anvendelige udgangsforbindelser
DK149854C (da) Analogifremgangsmaade til fremstilling af 1,2,4-oxadiazolin-5-oner eller farmaceutisk acceptable syreadditionssalte eller kvaternaere salte deraf samt mellemprodukter til anvendelse ved fremstillingen
SE7811382L (sv) Nya derivat av 4-amino-2-(piperazin-1-yl eller homopiperazin-1-yl)kinazolin med terapeutisk anvendbarhet
DK162882A (da) Imidazolderivater eller syreadditionssalte deraf,deres fremstilling og anvendelse
DK148826C (da) Analogifremgangsmaade til fremstilling af oxadiazolopyrimidinderivater eller salte deraf med baser og pyrimidinderivat til anvendelse som mellemprodukt ved denne fremgangsmaade
DK355587D0 (da) 2-penem-3-carboxylsyre-forbindelser og salte deraf samt deres fremstilling og anvendelse
NO863874D0 (no) Fremgangsmaate ved fremstilling av en azetidin-3-carboxylsyre eller et salt derav.
IT1095369B (it) Processo e reagente per la determinazione dell'acido urico
DK151797C (da) Analogifremgangsmaade til fremstilling af terbutalinderivater eller terapeutisk acceptable salte deraf
DK227281A (da) Quinoxalin-1,4-dioxidderivater eller biologisk acceptable salte deraf deres fremstilling og anvendelse i foderkoncentrater
DK288779A (da) 2-phenylamino-imidazoliner-(2) eller syreaddiitonssalte deraf fremgangsmaade til deres fremstilling samt deres anvendelse
IT1118123B (it) Composizione e procedimento per la colorazione di strisci cellulari
DK158783D0 (da) Phenoxyphenoxyprobionsyreestere eller salte deraf samt deres anvendelse som herbicider

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired